Initially, multiple MM patients show robust responses to bortezomib and other proteasome inhibitors; however, these patients could be heterogeneous for PSMB5 mutations causing an advantage through normal proteasomal function with the added benefit of less effective drug binding [159]. This evidence concerns the gene PSMB5 and Miyoshi myopathy.